title: Plasma concentrations of thyroid hormone in steers treated with Synovex-S and 3,5,3'-triiodothyronine.
abstract: This experiment examined the effect of daily administration of 3,5,3'-triiodothyronine (T3) on plasma profiles of T3, thyroxine (T4), 3,3',5'-triiodothyronine (reverse T3; rT3) and thyrotropin (TSH) in beef steers in which protein accretion was increased by using implants of Synovex-S (SYN). Twenty-four Angus-Hereford steers (302 +/- 16 kg) were individually fed a diet of a corn-based concentrate and silage mixture for 56 d at equal energy intake per steer (ME/unit BW.75). A 2 x 2 factorial arrangement of treatments was used in which treatments were SYN ear implants (200 mg of progesterone and 20 mg of estradiol benzoate) or no implants and s.c. injections of T3 in polyethylene glycol (2 micrograms of T3/kg BW every 48 h) or no injections of T3. Blood samples were collected every 2 wk. Plasma T3 concentration during the experimental period was increased in T3-treated steers (3.0 +/- .1 vs 2.2 +/- .1 ng/mL, P < .01) and was decreased in SYN-implanted steers (2.4 +/- .1 vs 2.7 +/- .1 ng/mL, P < .01). Plasma T4 and rT3 concentrations were reduced (22 +/- 4 vs 75 +/- 2 and .04 +/- .01 vs .12 +/- .01 ng/mL, respectively, P < .01) in T3-treated steers. Concurrently, plasma TSH concentration was decreased in T3-treated steers (.37 +/- .01 vs .51 +/- .02 ng/mL, P < .02). Synovex-S increased BW gain (21.0%, P < .01) and protein gain (35.6%, P < .01) compared with that of nonimplanted steers. Body weight gain and protein gain were not affected by treatment with T3.(ABSTRACT TRUNCATED AT 250 WORDS)
authors: Department of Animal Sciences, University of Maryland, College Park 20742.
authors: S
authors: S
authors: Kahl
authors: T S
authors: TS
authors: Rumsey
authors: T H
authors: TH
authors: Elsasser
authors: A S
authors: AS
authors: Kozak
mesh_terms: D000818:Animals; D002417:Cattle / Q000097:blood / Q000254:growth & development / Q000378:metabolism*; D004338:Drug Combinations; D004343:Drug Implants; D004347:Drug Interactions; D004958:Estradiol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D007279:Injections, Subcutaneous / Q000662:veterinary; D008297:Male; D011374:Progesterone / Q000008:administration & dosage / Q000494:pharmacology*; D013963:Thyroid Hormones / Q000097:blood*; D013972:Thyrotropin / Q000097:blood; D013974:Thyroxine / Q000097:blood; D014284:Triiodothyronine / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D014285:Triiodothyronine, Reverse / Q000097:blood; D015430:Weight Gain / Q000187:drug effects
chemical_list: D004338:Drug Combinations; D004343:Drug Implants; D013963:Thyroid Hormones; D014284:Triiodothyronine; D011374:Progesterone; D004958:Estradiol; D014285:Triiodothyronine, Reverse; C025370:estradiol benzoate, progesterone drug combination; D013972:Thyrotropin; D013974:Thyroxine